POSEIDA THERAPEUTICS INC's ticker is PSTX and the CUSIP is 73730P108. A total of 57 filers reported holding POSEIDA THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,026,091 | +31.8% | 5,052,979 | -2.5% | 0.00% | – |
| Q2 2023 | $9,124,305 | +56.8% | 5,184,265 | +174.3% | 0.00% | – |
| Q1 2023 | $5,820,655 | -36.1% | 1,889,823 | +9.9% | 0.00% | – |
| Q4 2022 | $9,111,093 | +78.2% | 1,719,074 | +18.7% | 0.00% | – |
| Q3 2022 | $5,113,000 | +77.5% | 1,447,918 | +29.7% | 0.00% | – |
| Q2 2022 | $2,881,000 | -74.0% | 1,116,733 | -54.8% | 0.00% | – |
| Q1 2022 | $11,062,000 | -36.4% | 2,468,954 | -3.3% | 0.00% | – |
| Q4 2021 | $17,385,000 | -5.9% | 2,552,990 | +0.8% | 0.00% | -100.0% |
| Q3 2021 | $18,466,000 | -27.5% | 2,533,139 | -0.3% | 0.00% | 0.0% |
| Q2 2021 | $25,470,000 | -5.6% | 2,541,825 | -10.1% | 0.00% | 0.0% |
| Q1 2021 | $26,994,000 | +58.9% | 2,826,556 | +82.5% | 0.00% | 0.0% |
| Q4 2020 | $16,987,000 | +100.5% | 1,548,443 | +62.1% | 0.00% | – |
| Q3 2020 | $8,473,000 | – | 955,255 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 1,043,267 | $2,692,000 | 1.92% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 380,606 | $982,000 | 0.30% |
| Pentwater Capital Management LP | 4,967,227 | $12,815,000 | 0.15% |
| Atom Investors LP | 55,827 | $144,000 | 0.06% |
| Corton Capital Inc. | 14,978 | $39,000 | 0.04% |
| Forefront Analytics, LLC | 23,370 | $61,000 | 0.03% |
| Delphia (USA) Inc. | 15,799 | $41,000 | 0.03% |
| Advisory Services Network, LLC | 259,571 | $670,000 | 0.02% |
| Laurion Capital Management LP | 545,700 | $1,408,000 | 0.02% |
| MCF Advisors LLC | 59,659 | $154,000 | 0.02% |